HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $9 Price Target

-3.73% Post

Aclaris Therapeutics, Inc.

ACRS

0.00

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ: ACRS) with a Buy and maintains $9 price target.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Option Signals | Opendoor Options Volume Soars to 890,000 Contracts After Earnings; Nvidia Sees Active Options Trading with 5.2 Million Contracts Traded

Shoulder Innovations Raises FY2025 Sales Guidance from $42.000M-$44.000M to $45.000M-$46.000M vs $43.173M Est

DocuSign (DOCU): Examining Valuation Opportunities as Momentum Softens

Nomad Foods (NYSE:NOMD): Rethinking Value After Softer Q3 Results and New Leadership Moves

FOREX-Dollar tentative as traders mull December Fed cut on weakening US jobs market

UPDATE 1-Dutch bank ABN Amro buys domestic peer NIBC Bank for $1.1 billion

Owens Corning (OC): Assessing Valuation After Q3 Losses and Goodwill Impairment

Financial Morning Summary | Dividend Alert for LEEJAM SPORTS(1830); Alramz to List 12.9M Shares on TASI; Circle Down 12.2% After Earnings; Trump Ends Longest US Government Shutdown